GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Naturewise Biotech & Medicals Corp (ROCO:4732) » Definitions » EV-to-EBITDA

Naturewise Biotech & Medicals (ROCO:4732) EV-to-EBITDA : 41.51 (As of Jun. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Naturewise Biotech & Medicals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Naturewise Biotech & Medicals's enterprise value is NT$846.5 Mil. Naturewise Biotech & Medicals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$20.4 Mil. Therefore, Naturewise Biotech & Medicals's EV-to-EBITDA for today is 41.51.

The historical rank and industry rank for Naturewise Biotech & Medicals's EV-to-EBITDA or its related term are showing as below:

ROCO:4732' s EV-to-EBITDA Range Over the Past 10 Years
Min: -96.58   Med: -4.56   Max: 43.54
Current: 41.51

During the past 13 years, the highest EV-to-EBITDA of Naturewise Biotech & Medicals was 43.54. The lowest was -96.58. And the median was -4.56.

ROCO:4732's EV-to-EBITDA is ranked worse than
83.74% of 449 companies
in the Biotechnology industry
Industry Median: 9.2 vs ROCO:4732: 41.51

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), Naturewise Biotech & Medicals's stock price is NT$26.60. Naturewise Biotech & Medicals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.200. Therefore, Naturewise Biotech & Medicals's PE Ratio for today is 133.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Naturewise Biotech & Medicals EV-to-EBITDA Historical Data

The historical data trend for Naturewise Biotech & Medicals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Naturewise Biotech & Medicals EV-to-EBITDA Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.86 11.02 46.93 30.27 43.81

Naturewise Biotech & Medicals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.93 - 30.27 - 43.81

Competitive Comparison of Naturewise Biotech & Medicals's EV-to-EBITDA

For the Biotechnology subindustry, Naturewise Biotech & Medicals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Naturewise Biotech & Medicals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Naturewise Biotech & Medicals's EV-to-EBITDA falls into.



Naturewise Biotech & Medicals EV-to-EBITDA Calculation

Naturewise Biotech & Medicals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=846.533/20.392
=41.51

Naturewise Biotech & Medicals's current Enterprise Value is NT$846.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturewise Biotech & Medicals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$20.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Naturewise Biotech & Medicals  (ROCO:4732) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Naturewise Biotech & Medicals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=26.60/0.200
=133.00

Naturewise Biotech & Medicals's share price for today is NT$26.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturewise Biotech & Medicals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.200.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Naturewise Biotech & Medicals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Naturewise Biotech & Medicals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Naturewise Biotech & Medicals (ROCO:4732) Business Description

Traded in Other Exchanges
N/A
Address
No. 36, Bade Road, 6th Floor, Section 3, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.

Naturewise Biotech & Medicals (ROCO:4732) Headlines

No Headlines